Comparison of a thymine challenge test and endogenous uracil –dihydrouracil levels for assessment of fluoropyrimidine toxicity risk
ConclusionsThe endogenous uracil-based parameters, adjusted to CrCL, were more predictive of increased risk of severe fluoropyrimidine toxicity thanDPYD genotyping. However, endogenous U measurement detected fewer cases of severe toxicity than the THY challenge test. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - March 9, 2021 Category: Cancer & Oncology Source Type: research

Detecting DPD deficiency: when perfect is the enemy of good
(Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - March 9, 2021 Category: Cancer & Oncology Source Type: research

A pharmacologically-based approach to high dose methotrexate administration to investigate nephrotoxicity and acute kidney injury biomarkers in children and adolescents with newly diagnosed osteosarcoma
ConclusionsReducing peak serum and urine MTX concentration by prolonging the infusion duration did not alter risk of acute kidney injury. GFRcysC was decreased at the end of therapy. Proteinuria and elevations in AKI biomarkers indicate that direct tubular damage contributes to HDMTX nephrotoxicity.Clinical TrialNCT01848457. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - March 7, 2021 Category: Cancer & Oncology Source Type: research

Pharmacokinetics of UGN-101, a mitomycin-containing reverse thermal gel instilled via retrograde catheter for the treatment of low-grade upper tract urothelial carcinoma
ConclusionThe reverse thermal gel formulation of UGN-101 is associated with higher concentration and extended dwell time of mitomycin in contact with the urothelium of the upper urinary tract while limiting systemic absorption of mitomycin.RegistrationNCT02793128; registered June 8, 2016. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - March 7, 2021 Category: Cancer & Oncology Source Type: research

Venous thromboembolism incidence and risk factors in adults with acute lymphoblastic leukemia treated with and without pegylated E. coli asparaginase-containing regimens
ConclusionThis study confirms PegA as a risk factor for VTE in patients with ALL. Risk factors among those receiving PegA include higher BMI and pre-T/T cell ALL. ATIII repletion was not shown to be protective against VTE. There was a higher incidence of VTE in patients who received PegA with non-O compared to O blood type, but the precise correlation is uncertain. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - March 7, 2021 Category: Cancer & Oncology Source Type: research

Clinical significance of circulating tumor cells in the response to trastuzumab for HER2-negative metastatic gastric cancer
ConclusionThe present results indicate the potential clinical utility of trastuzumab combined chemotherapy in patients with HER2-positive CTCs even if they are histologically HER2-negative. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - February 28, 2021 Category: Cancer & Oncology Source Type: research

Associations among plasma concentrations of regorafenib and its metabolites, adverse events, and ABCG2 polymorphisms in patients with metastatic colorectal cancers
ConclusionThis study showed that theCtrough of regorafenib was associated with bilirubin increase, and also clarified for the first time that theCtrough of M5 was significantly correlated with hypertension and severe rash. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - February 26, 2021 Category: Cancer & Oncology Source Type: research

A phase I pharmacokinetic and safety study of Paclitaxel Injection Concentrate for Nano-dispersion (PICN) alone and in combination with carboplatin in patients with advanced solid malignancies and biliary tract cancers
ConclusionThis study demonstrated the safety and stable pharmacokinetics of PICN as a monotherapy and in combination with carboplatin. Single-agent PICN showed promising antitumor activity in advanced BTCs, warranting further studies to investigate its role in gastrointestinal cancers. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - February 26, 2021 Category: Cancer & Oncology Source Type: research

Early myelostimulation in patients with locally advanced gastric cancer after fluorouracil plus platinum-based neoadjuvant chemotherapy is related to poor prognosis
ConclusionThe"myelostimulation" that occurs in patients with LAGC in the early stage (3 –5 days) after fluorouracil plus platinum-based NACT is related to a poor prognosis, which is a simple and effective method to screen related patients with unfavored outcomes. Notably, the increase in absolute neutrophil count and platelet count has been proved to be an independent risk factor. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - February 21, 2021 Category: Cancer & Oncology Source Type: research

Irinotecan-induced intestinal mucositis in mice: a histopathological study
ConclusionsThe data obtained in the present study provides new evidence that irinotecan-induced intestinal mucositis highly affects small intestine and colon, further contributing to establish criteria in light of the histopathological changes induced by irinotecan during intestinal mucositis and facilitating inter-study comparisons. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - February 18, 2021 Category: Cancer & Oncology Source Type: research

Trilaciclib dose selection: an integrated pharmacokinetic and pharmacodynamic analysis of preclinical data and Phase Ib/IIa studies in patients with extensive-stage small cell lung cancer
ConclusionIntegrated PK/PD, safety, and efficacy data support 240  mg/m2 as the RP2D for trilaciclib.ClinicalTrials.gov IdentifiersNCT02243150; NCT02499770; NCT02514447. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - February 17, 2021 Category: Cancer & Oncology Source Type: research

Severe toxicity of capecitabine in a patient with DPD deficiency after a safe FEC-100 experience: why we should test DPD deficiency in all patients before high-dose fluoropyrimidines
We report the case of a 44-year-old patient who experienced severe toxicity while being treated with capecitabine at standard dose for metastatic breast cancer. As the patient had already received 5-FU within the FEC protocol (5-FU 500  mg/m2, epirubicin 100  mg/m2, and cyclophosphamide 500  mg/m2) 10  years ago without experiencing any severe adverse event, no DPD deficiency testing was performed before capecitabine treatment. Nevertheless, she experienced severe diarrhea and grade 2 hand–foot syndrome from the first cycle, forcing her to stop the treatment. Phenotypic and genotypic investiga tion of DPD activity re...
Source: Cancer Chemotherapy and Pharmacology - February 15, 2021 Category: Cancer & Oncology Source Type: research

Phase I study of JAK1/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer
ConclusionThe combination of ruxolitinib and weekly paclitaxel was well tolerated with evidence of clinical activity. Further analysis of this combination is ongoing (NCT02041429).Trial registrationNCT02041429. Date of registration: January 22, 2014. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - February 14, 2021 Category: Cancer & Oncology Source Type: research

Carboxylesterase 1 polymorphisms are associated with clinical outcomes in gastroenteric cancer patients treated with capecitabine
ConclusionsThe identifiedCES1 polymorphisms might provide guide for the identification of gastroenteric cancer patients who were likely to benefit from capecitabine-based chemotherapy. (Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - February 14, 2021 Category: Cancer & Oncology Source Type: research

Acknowledgement of reviewers 2020
(Source: Cancer Chemotherapy and Pharmacology)
Source: Cancer Chemotherapy and Pharmacology - February 10, 2021 Category: Cancer & Oncology Source Type: research